Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001

  • Addressing high unmet medical need in locally advanced soft tissue sarcoma
  • Targeted tumor treatment independent of specific molecular targets or tumor subtypes

Munich, Germany – May 24, 2023 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced that the first patient has been dosed in April 2023 in the ongoing Phase 1 trial of its lead program THE001. Additional patients will be enrolled following a 6-week monitoring period that includes two treatment cycles.